DeCure for Rhizomelic chondrodysplasia punctata type 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for rhizomelic chondrodysplasia punctata type 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRhizomelic chondrodysplasia punctata type 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rhizomelic chondrodysplasia punctata type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Rhizomelic chondrodysplasia punctata type 2 is a peroxisomal disorder recognisable at birth by typical physical and radiological features. Most patients die young; some survive into their teens but all are severely retarded. Peroxisomal investigations may help define prognosis for an individual patient and are useful for antenatal diagnosis. The rhizomelic form is rare, with only 72 cases reported up to 1995. The prognosis is bad and death usually occurs within the first year of age.
A 52-day-old child presented with rhizomelic micromelia, characteristic facies, suction difficulty, and anthropometric measures below expected for age. Skeletal radiographs showed shortening of humeri and femora and stippled calcifications at shoulders, hips, and knee joints. The patient also had a heart malformation, a less common manifestation. Diagnosis was made on clinical and radiological criteria because the biochemical markers could not be tested.
A newborn with intrauterine growth restriction, rhizomelic dwarfism, and suspected chondrodysplasia punctata was initially thought to have osteogenesis imperfecta, but a skeletal survey suggested mucolipidosis II alpha/beta. Sequencing revealed compound heterozygosity for a reported pathogenic and a novel expected pathogenic GNPTAB variant. Molecular testing for autosomal recessive osteogenesis imperfecta identified a SERPINF1 variant.
What is still missing are prospective natural history data to define the full spectrum of disease progression, reliable biochemical or genetic markers for routine diagnosis of the type 2 form, and any clinical trial testing a treatment. No drug is mentioned in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2019 · 21 citations · open access
Rhizomelic chondrodysplasia punctata morbidity and mortality, an update
AbstractDr. Michael Bober is a PI for A Prospective Natural History Study of Patients with Rhizomelic Chondrodysplasia Punctata, sponsored by Med-Life Discoveries LP. Dr. Michael Bober, Dr. Nancy Braverman, and Dr. Poll-Thé are also members of Medical Advisory Board for RhizoKids International. The other authors have no conflict of interest to declare. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Jornal de Pediatria · 2003 · 11 citations · open access
Condrodisplasia puntiforme forma rizomélica: relato de caso
AbstractOBJECTIVE: To report a case of rhizomelic chondrodysplasia punctata and present a brief literature review. DESCRIPTION: The authors report the case of a 52-day-old child presenting the main findings of the syndrome: rhizomelic micromelia, characteristic facies, suction difficulty and anthropometric measures below the expected indexes for his age. Skeletal radiographies showed humeri and femora shortening and calcifications stippling on shoulders, hips and knees joints. The patient also presented heart malformation, a less common manifestation of the syndrome. COMMENTS: The rhizomelic form of chondrodysplasia punctata is rare, with only 72 cases reported until 1995. The prognosis is bad and death usually occurs within the first year of age. The case presented here was diagnosed based on clinical and radiological criteria, due to the impossibility of searching for the peculiar biochemical markers.
Ophthalmic Paediatrics and Genetics · 1987 · 8 citations
Peroxisomal dysfunction in chondrodysplasia punctata, rhizomelic type
AbstractThe rhizomelic type of chondrodysplasia punctata (RCDP) is recognizable at birth because of the typical phenotype and radiological features. Most patients die young, some survive until their teens but all are severely retarded. Recent studies showed RCDP to be a peroxisomal disorder. Peroxisomal investigations may be important in defining the prognosis for an individual patient, and are definitely of use in antenatal diagnosis.
Journal of health disparities research and practice · 2014 · 2 citations · open access
Sexual Dysfunction among Latino Men and Women with Poorly Controlled Diabetes
AbstractWe report on a newborn with IUGR, rhizomelic dwarfism, and suspected chondrodysplasia punctata. At birth, OI was suspected; however, a skeletal survey suggested ML II alpha/beta. Sequencing revealed compound heterozygosity for a reported pathogenic and novel but expected pathogenic <i>GNPTAB</i> variant. Molecular testing for autosomal recessive OI identified a <i>SERPINF1</i> variant.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
